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MCP-1: a player in the pathogenesis of
progression of renal diseases
There is an increasing body of evidence that the
CC chemokine monocyte chemoattractant protein-1
(MCP-1) plays a major role in the pathogenesis of
progression of renal failure. This is based on observa-
tions both in various animal models of renal damage
and in different types of human renal disease (for
review, see [1]). Locally produced MCP-1 seems to be
particularly involved in the initiation and progression
of tubulointerstitial damage. The latter has been
documented in experiments using transgenic mice
with nephrotic serum-induced nephritis: compared
with wild-type mice, MCP-1-deficient mice exhibit
less tubulointerstitial lesions, but they exhibit no
differences in glomerular lesions [2]. There is, however,
evidence that MCP-1 also plays a role in the progres-
sion of glomerular lesions, since glomerular expression
of MCP-1 correlates with the degree of renal damage
in inflammatory [3] and non-inflammatory [4] models
of glomerular injury. Furthermore, in humans with
crescentic glomerulonephritis, MCP-1 is not only
expressed in tubular epithelial cells and leukocytes
infiltrating the tubulointerstitium, but also in crescents
and parietal epithelium [5]. In experimental crescentic
glomerulonephritis, administration of antibodies to
MCP-1 decreases the extent of proteinuria, reduces
glomerulosclerosis and improves renal dysfunction [6].
Of importance, a consistent increase of urinary
MCP-1 concentration is found in patients or animals
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with a diseased kidney, and this correlates with the
degree of urinary albuminuprotein excretion and renal
damage [7–10]. In addition to mesangial cells, endo-
thelial cells and infiltrating mononuclear cells [11,12],
tubular epithelial cells [12,13] seem to be the major
source of MCP-1 in urine. The increased production of
MCP-1 by tubular epithelial cells is due to: (i) stimula-
tion by cytokines [14,15]; and (ii) exposure to urinary
proteins [16]. Both are mediators of progressive renal
damage [17].
Interestingly, therapy with an angiotensin-converting
enzyme (ACE) inhibitor or an angiotensin II receptor
type 1 (AT1) antagonist is able to abrogate the renal
expression of MCP-1 [18,19]. This may not only be
due to reduction of proteinuria. Rat mesangial cells
in vitro produce increasing amounts of MCP-1 in
response to increasing external pressure, suggesting
that MCP-1 may be a mediator of the adverse effects
of intraglomerular hypertension [20]. The latter is an
important factor in the genesis of progressive glomerular
damage, which is attenuated by therapy with an ACE
inhibitor or an AT1 receptor antagonist. Taken toge-
ther, MCP-1 seems to be of pivotal importance in
the pathogenesis of progression of renal damage and
failure.
To date, the classic perception of MCP-1 was that
its main property is the attraction of monocytesu
macrophages. These inflammatory cells in turn secrete
cytokines and chemokines, fostering inflammation and
fibrosis. Increased synthesis of cytokines and chemo-
kines by infiltrating inflammatory cells and resident
renal cells has been documented in various forms of
glomerulonephritis and tubulointerstitial nephritis. It
has been suggested that they are important mediators
of progressive renal failure in vivo [1]. Recent data
[21,22] indicate that the role of MCP-1 goes beyond
that of a simple chemoattractant protein.
MCP-1 induces an inflammatory activation of
human tubular epithelial cells
Recent data from our group provide evidence that
increased concentrations of MCP-1 in the diseased
kidney may be an important factor contributing per se
to increased production of cytokines and adhesion
molecules. We demonstrated that MCP-1 specifically
activates tubular epithelial cells in vitro [21], leading
to a time- and dose-dependent increase in secretion
of the proinflammatory cytokine interleukin-6
(IL-6) and expression of the intracellular adhesion
molecule-1 (ICAM-1) via Gi-protein-, protein kinase
C (PKC)- and intracellular Ca2q-dependent mechan-
isms (Figure 1). MCP-1 activated: (i) the transcription
factor nuclear factor-kB (NF-kB), a transcription
factor commonly involved in inflammatory and
immune responses, and (ii) activating protein-1 (AP-1),
a transcription factor involved in inflammatory and
growth responses. Both NF-kB and AP-1 were involved
in the MCP-1-mediated induction of IL-6. In contrast
to IL-6 release, MCP-1-induced ICAM-1 expression
was predominantly dependent on NF-kB activation
(Figure 2). IL-6 has been suggested to contribute to
Fig. 1. Scheme of the intracellular signalling pathways of MCP-1 in a human tubular epithelial cell.
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progression of renal diseases [23,24] because its renal
expression correlates with the degree of mesangial
hyperproliferation, tubular atrophy, and the intensity
of interstitial infiltrates [25,26]. De novo expression
of the adhesion molecule ICAM-1 by tubular epithelial
cells and increased expression by interstitial and glome-
rular cells has been observed in different forms
of glomerulonephritis, tubulointerstitial inflammation
and renal allograft rejection [27]. Thus, the observed
effects of MCP-1 on tubular epithelial cells in vitro
may be critical steps during progression in vivo.
MCP-1 does not only exhibit direct effects on
tubular epithelial cells, but also on another cell type
that plays a role in progressive renal damage, i.e.
vascular smooth muscle cells [22]. Stimulation of
vascular smooth muscle cells with MCP-1 induced
proliferation and resulted in a concentration- and time-
dependent release of IL-6. Similar to tubular epithelial
cells, this effect was mediated via Gi-protein, PKC and
NF-kB. MCP-1 also induced extracellular signal-
regulated kinase (ERK), which, along with IL-6
release, was Gi-protein-dependent. MCP-1-induced,
proliferation of vascular smooth muscle cells, which
was ERK-dependent. MCP-1 stimulated the binding
activity of NF-kB and of AP-1. NF-kB was involved in
IL-6 release by MCP-1, whereas proliferation was
dependent on AP-1, demonstrating that, as in tubular
epithelial cells, MCP-1 induces differential activation
of NF-kB and AP-1 in vascular smooth muscle cells.
Thus, these latter data do not only propose a new
mechanism for the proatherogenic effect of MCP-1
in the progression of cardiovascular disease, but also
implicate MCP-1 as a factor leading to vascular
damage in the diseased kidney.
Which receptor(s) is responsible for the mediation
of effects of MCP-1 on human tubular epithelial
cells?
Chemokines exert their effects through binding to
G-protein-coupled receptors on the surface of leukocytes
targeted for activation and migration. These receptors,
once activated, trigger a set of cellular reactions that
result in inositol triphosphate formation, intracellular
calcium release, and PKC activation [28]. The classic
MCP-1 receptors belong to the family of heptahelical,
pertussis-sensitive, G-protein-coupled receptors [29].
The MCP-1 receptor on tubular epithelial cells appears
to be coupled to Gi-protein activation [21]. These
findings are in accordance with our observations in
vascular smooth muscle cells [22], as well as data of
others [29,30].
As in leukocytes, MCP-1-induced up-regulation of
IL-6 synthesis and ICAM-1 expression by human
tubular epithelial cells are dependent on PKC and
intracellular Ca2q (Ca2qi ) [21]. Similarly, Schecter
et al. [30] demonstrated that the induction of tissue
factor by MCP-1 in human vascular smooth muscle
cells required Ca2qi mobilization and that it was PKC-
dependent. Therefore, although currently unproven,
it is likely that MCP-1-signalling is mediated by the
classical PKC subgroups a, b or c.
To date, in renal tissue of humans and experimental
animals, expression of CCR1-5 mRNA transcripts
were detected only in infiltrating mononuclear cells.
Two MCP-1 receptors, generated by alternative spli-
cing and designated as CCR2A and -B, have been
cloned in human monocytes [31]. On the basis of
our polymerase chain reaction and flow cytometry
Fig. 2. Scheme of the direct and indirect effects of MCP-1 on human tubular epithelial cells (TECs).
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analysis studies, the MCP-1 receptor on human tubu-
lar epithelial cells is distinct from these two receptors
[21]. Furthermore, the MCP-1 receptor on human
tubular epithelial cells is also distinct from the CCR1,
CCR3, CCR4 and CCR5 receptors. Antibodies against
CCR1–5 failed to inhibit the specific effects of MCP-1
on tubular epithelial cells. However, binding studies
for MCP-1 revealed that cultured human tubular
epithelial cells express a MCP-1 binding protein on
the cell surface. The possibility that the effects of
MCP-1 on tubular epithelial cells are mediated via an
endosome-lysosomal pathway was ruled out [21].
Taken together, the above results implicate that it is
likely that the MCP-1 receptor on human tubular
epithelial cells is different from previously cloned
CC chemokine receptors. The nature of the MCP-1
receptor(s) on human tubular epithelial cells, which
seems to be Gi-protein coupled, remains to be
determined (Figure 1).
Conclusion
MCP-1 can activate tubular epithelial cells directly
in vitro. This action of MCP-1 on a resident renal cell
had so far remained unknown, but had been des-
cribed in cultured vascular smooth muscle cells [22,30].
The MCP-1-mediated activation of tubular epithelial
cells is consistent with the notion that MCP-1 contri-
butes to tubulointerstitial inflammation, which is a
hallmark of progressive renal disease [17]. Importantly,
tubulointerstitial rather than glomerular damage cor-
relates best with the loss of renal function and the risk
of progression to end-stage renal failure. Actually,
there is a strict correlation between tubular atrophy,
interstitial fibrosis, the extent of interstitial infiltrates
and renal dysfunction [32]. The direct effects of MCP-1
on vascular smooth muscle cells [22] may not only be
of importance in the progression of cardiovascular
damage in general, but also in the progression of
vascular lesions in the kidney, which could contribute
further to progression of renal failure.
Previous studies focused on the role of MCP-1 in
renal inflammation and its induction of inflammatory
signals [1]. Our recent data suggest that MCP-1 is more
than just a chemoattractant. Rather, MCP-1 can
directly elicit an inflammatory response by inducing
cytokine and adhesion molecule expression in the
kidney. This is an important new mechanism in the
pathogenesis of tubulointerstitial inflammation.
Note added in proof
Kru¨ger et al. [33] recently reported that recipients of a
renal allograft who are carriers of the MCP-1-2518
(GuG) polymorphism, i.e. a genotype characterized
by increased production of MCP-1 by mononuclear
cells, have a significantly reduced mean graft survival
compared with the heterozygous (AuG) or wild-type
(AuA) allele carriers. In contrast, carriers of the 64I
mutation of the CCR2 receptor, a genotype which
presumably alters CCR2 expression or function, had
no increase of mean renal allograft survival. These
in vivo data support our in vitro findings [21], i.e.
specific inflammatory activation of human tubular
epithelial cells by MCP-1 despite the lack of CCR2
receptors on these cells.
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